Table 1 Clinical features and concomitant treatment of the cohort
SLE patients (n = 18) | |
|---|---|
Baseline SLEDAI, median (IQR) | 6 (4) |
Follow-up SLEDAI, median (IQR) | 5 (2)* |
Indication for starting belimumab | |
Musculoskeletal involvement, n (%) | 12 (66.7) |
Mucocutaneous involvement, n (%) | 5 (27.8) |
Lung involvement, n (%) | 1 (5.5) |
Concomitant treatment | |
Glucocorticoids, n (%) | 18 (100) |
Hydroxychloroquine, n (%) | 17 (94.4) |
Mycophenolate, n (%) | 5 (27.8) |
Azathioprine, n (%) | 4 (22.2) |
Cyclosporine, n (%) | 3 (16.7) |
Methotrexate, n (%) | 2 (11.1) |
Thalidomide, n (%) | 1 (5.5) |